Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa
about
The use of tombramycin in the management of severe infections. Clinical and pharmacological data.Comparative antimicrobial activity of O-demethylfortimicin A, a derivative of fortimicin A.BL-P1654, ticarcillin, and carbenicillin: in vitro comparison alone and in combination with gentamicin against Pseudomonas aeruginosaActivity of newer aminoglycosides and carbenicillin, alone and in combination, against gentamicin-resistant Pseudomonas aeruginosa.Amikacin and cephalothin: empiric regimen for granulocytopenic cancer patients.Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy.Effect of calcium, magnesium, and zinc on ticarcillin and tobramycin alone and in combination against Pseudomonas aeruginosa.Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearanceCombination therapy for treatment of infections with gram-negative bacteria.Pirbenicillin: comparison with carbenicillin and BL-P1654, alone and with gentamicin, against Pseudomonas aeruginosa.Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo.Effects of gestational age, birth weight, and hypoxemia on pharmacokinetics of amikacin in serum of infants.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Controversies in the management of febrile neutropenic cancer patients.Unpredictable response of Pseudomonas aeruginosa to synergistic antibiotic combinations in vitroIn vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aerurginosa.Global and effective synergism of amikacin, gentamicin or tobramycin when combined with carbenicillin against Pseudomonas aeruginosa.Chemotherapy of chronic infections with mucoid Pseudomonas aeruginosa in lower airways of patients with cystic fibrosis.Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics.Synergistic activities of fortimicin A and beta-lactam antibiotics against Pseudomonas aeruginosa.Microdilution transfer plate technique for determining in vitro synergy of antimicrobial agents.In vitro synergism between carbenicillin and aminoglycosidic aminocyclitols against Acinetobacter calcoaceticus var. anitratusEffect of time and concentration upon interaction between gentamicin, tobramycin, Netilmicin, or amikacin and carbenicillin or ticarcillin.Bronchial secretion levels of amikacin.Empiric treatment of fever in acute leukaemia with tobramycin-cephalothin, and the escape clause provision of corticosteroids.Susceptibility of Pseudomonas aeruginosa to tobramycin or gentamicin alone and combined with carbenicillin.In vitro synergistic effect of netilmicin, a new aminoglycoside antibiotic.In vitro activity of gentamicin, amikacin and netilmicin alone and in combination with carbenicillin against Serratia marcescens.Antibiotic synergy and antagonism against clinical isolates of Klebsiella species.Sensitivity of gram-negative bacteria to six aminoglycoside antibiotics.Comparative activity of tobramycin and gentamicin against Pseudomonas, Proteus and Providencia species.Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability.
P2860
Q32059722-9DF125AF-5A5E-4120-BE7E-33334E0EB6F4Q33736268-5D9F5C5D-F533-4B5D-8724-88038A157AC7Q34922337-2A376349-1DD3-42F3-8FBD-E742CB024988Q34979815-E8EBDB70-3F84-4D85-875B-320ECE8B8DF1Q34988087-69B97E93-C62F-4765-923D-376694D67633Q35540674-544D9A22-0A1C-4B6A-AA2D-CEC76CD9CC9EQ35761276-4E83083A-6F48-451C-942A-9B654E664733Q36089167-FA36561D-2A05-4815-A882-B2DDF61E10B4Q36156077-A22075CD-E860-45AE-A557-AE3461F73500Q36460617-BDEECEA5-5051-42AC-A57C-EC38EE7551A4Q36463439-5CD605B8-E705-49C5-9FBC-D98D6965433BQ36463807-CA7891E3-7A0C-490E-90BD-8E4F716BC94EQ37563029-E8053314-AB4C-4BA4-86D7-ADF0FA2F916AQ39603225-17CB8D08-9A49-4292-9619-3D261B7D7F7EQ39604645-3A5447DF-662E-4223-B1B3-D5F8F84B25B9Q39611982-E94EF957-9577-4ADC-934B-F506F49851B2Q39693899-DAD9C2A1-20C7-43B1-8CAE-E7A8D3ABA1DBQ39706431-E3AD9D50-3E8A-46E1-AD1B-92163FB90A85Q39849094-A03FD907-20FE-4B5A-AAF5-2901E7BF8A9FQ39855408-D21656BA-DC5C-43D6-BCE8-6671EB3A4364Q40616737-56BF19B8-10B1-43EC-A365-CA3FDA82EBB5Q40617563-42A18339-F98A-4978-AA4B-3EACBE6743C4Q40620360-19D67AE5-B48A-4B7B-A697-58078EDD84D6Q40621410-2D418194-4FEF-46CD-AC22-17B3406B0C5BQ40864054-DACC1005-B0BD-4AD5-A1F6-8CCCD59F21D3Q40944878-2D2BB7AC-7658-4A6E-BE90-421EA714D399Q40947357-BA828380-C7FC-4CBE-A693-31DB4EB72AAAQ40947769-3033E56F-4573-49CF-9FA6-A4F65C4DA019Q40947781-8BB5394E-1D1D-44D8-AEB4-2B0CE202EC7CQ41249926-16DBDC06-76CA-4BD6-8685-A6A5B8160833Q42148113-C3CB29BA-5274-4483-912D-D650E45F67C3Q47784438-92FE4463-AD8D-45F8-B391-BE2EB646C1C8
P2860
Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa
description
1974 nî lūn-bûn
@nan
1974年の論文
@ja
1974年論文
@yue
1974年論文
@zh-hant
1974年論文
@zh-hk
1974年論文
@zh-mo
1974年論文
@zh-tw
1974年论文
@wuu
1974年论文
@zh
1974年论文
@zh-cn
name
Comparative activity of tobram ...... against Pseudomonas aeruginosa
@ast
Comparative activity of tobram ...... against Pseudomonas aeruginosa
@en
type
label
Comparative activity of tobram ...... against Pseudomonas aeruginosa
@ast
Comparative activity of tobram ...... against Pseudomonas aeruginosa
@en
prefLabel
Comparative activity of tobram ...... against Pseudomonas aeruginosa
@ast
Comparative activity of tobram ...... against Pseudomonas aeruginosa
@en
P2093
P2860
P356
P1476
Comparative activity of tobram ...... against Pseudomonas aeruginosa
@en
P2093
Hornick RB
Schimpff SC
Standiford HC
P2860
P304
P356
10.1128/AAC.6.4.442
P407
P577
1974-10-01T00:00:00Z